


M42, AstraZeneca & SOPHiA GENETICS launch liquid biopsy initiative in UAE

07 June 2025 | News

To serve as a foundation for broader expansion across the Middle East, excluding Saudi Arabia



M42, a global health leader powered by technology, continues to pioneer artificial intelligence (AI) and medical and clinical solutions as part of its mission to revolutionise health in the UAE and globally.

In a major advancement for precision oncology, M42 has announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of cancers.

As part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood draw. This approach does not replace but rather complements routine cancer screenings and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer profile.

Over the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the UAE.

The new testing programme will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the region. Validation studies are set to commence shortly at

Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 2025.